Article Text

PDF
CASE REPORT
Concurrent Sweet’s syndrome and myopericarditis following mesalamine therapy
  1. Samuel A Shabtaie1,
  2. Nicholas Y Tan1,
  3. Riddhi S Parikh1,
  4. Konstantinos A Papadakis2
  1. 1Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
  2. 2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to Dr Samuel A Shabtaie, shabtaie.samuel{at}mayo.edu

Summary

Mesalamine, or 5-aminosalicylic acid, is a frequently used medication for the treatment of inflammatory bowel disease (IBD). We report the case of a 40-year-old woman recently diagnosed with IBD and started on mesalamine, who presented with new onset tender skin lesions 3 days following medication administration. One day following the onset of skin lesions, the patient developed acute chest pain, shortness of breath, ECG changes, troponemia, C-reactive protein elevation and pericardial enhancement on cardiac MRI consistent with myopericarditis. Subsequent skin biopsy confirmed the diagnosis of Sweet’s syndrome. On cessation of the drug, both the skin lesions and the cardiac symptoms resolved in combination with anti-inflammatory therapy. While mesalamine has been previously associated with myocarditis and pericarditis, to our knowledge this is the first case of coexisting Sweet’s syndrome with myopericarditis in the context of mesalamine therapy.

  • inflammatory bowel disease
  • crohn’s disease
  • drugs: gastrointestinal system
  • pericardial disease
  • unwanted effects / adverse reactions
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors SAS was involved in the conception/design of the work, data collection, interpretation, critical revision of the article and final approval of the published version. NYT was involved in the conception/design of the work, data collection, interpretation, critical revision of the article and final approval of the published version. RSP was involved in data collection, interpretation, critical revision of the article and final approval of the published version. KAP was involved in data collection, interpretation, critical revision of the article and final approval of the published version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.